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Abstract
Background: Dengue virus (DENV) is a mosquito-transmitted positive single strand RNA virus belonging to the Flaviviridae
family. DENV causes dengue fever, currently the world’s fastest-spreading tropical disease. Severe forms of the disease like
dengue hemorrhagic fever and dengue shock syndrome are life-threatening. There is no specific treatment and no anti-
DENV vaccines. Our recent data suggests that the amino terminal cytoplasmic region of the dengue virus non-structural
protein 4A (NS4A) comprising amino acid residues 1 to 48 forms an amphipathic helix in the presence of membranes. Its
amphipathic character was shown to be essential for viral replication. NMR-based structure-function analysis of the NS4A
amino terminal region depends on its milligram-scale production and labeling with NMR active isotopes.
Methodology/Principal Findings: This report describes the optimization of a uniform procedure for the expression and
purification of the wild type NS4A(1-48) peptide and a peptide derived from a replication-deficient mutant NS4A(1-48; L6E,
M10E) with disrupted amphipathic nature. A codon-optimized, synthetic gene for NS4A(1-48) was expressed as a fusion
with a GST-GB1 dual tag in E. coli. Tobacco etch virus (TEV) protease mediated cleavage generated NS4A(1-48) peptides
without any artificial overhang. Using the described protocol up to 4 milligrams of the wild type or up to 5 milligrams of the
mutant peptide were obtained from a one-liter culture. Isotopic labeling of the peptides was achieved and initial NMR
spectra were recorded.
Conclusions/Significance: Small molecules targeting amphipathic helices in the related Hepatitis C virus were shown to
inhibit viral replication, representing a new class of antiviral drugs. These findings highlight the need for an efficient
procedure that provides large quantities of the amphipathic helix containing NS4A peptides. The double tag strategy
presented in this manuscript answers these needs yielding amounts that are sufficient for comprehensive biophysical and
structural studies, which might reveal new drug targets.
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Introduction
Dengue fever is currently the fastest-spreading tropical disease
in the world, with more than 2.5 billion people at risk. Dengue
virus (DENV), the causative agent of this disease, is estimated to
infect 390 million people across all continents each year [1].
DENV is transmitted by the bite of female mosquitoes. DENV
causes flu-like symptoms in most of the infected patients, but
severe forms of the disease like dengue hemorrhagic fever and
dengue shock syndrome are life-threatening. There is no specific
treatment and no anti-DENV vaccines.
DENV is a positive single strand RNA virus of the Flaviviridae
family. Its genome is translated into a single polyprotein, which is
subsequently cleaved into three structural and seven non-structural
(NS) proteins. DENV replicates its RNA genome in replication
complexes (RCs), which are associated with modified intracellular
membranes [2]. While the viral structural proteins compose the
mature virion, the NS proteins together with the viral RNA and
host factors generate the viral RC. NS4A is an endoplasmic
reticulum (ER)-localized, 16 kDa transmembrane protein, which
is an essential component of the viral RC. NS4A has been
suggested to be involved in inducing host membrane alterations
that resemble the virus-induced membrane structures [3]. A
membrane remodeling function of NS4A was also reported in
other flaviviruses [4,5].
Recently, we identified a conserved amphipathic helix (AH) in
the cytoplasmic, amino terminal region of NS4A (amino acid
residues 1–48) that is essential for viral replication [6]. AHs are a
helical protein regions in which one face of the helix is
hydrophobic while the opposite face is hydrophilic [8]. In contrast
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to transmembrane domains that span the membrane bilayer, AHs
often serve as in-plane membrane anchors [7]. Peptides that are
predicted to form amphipathic helices are frequently unstructured
in buffer devoid of membranes but adopt a helical conformation
upon association with membranes or in a membrane mimicking
environment. In addition AHs can contribute to membrane
curvature [8–10] or mediate protein-protein-interactions. AHs in
proteins of several positive strand RNA viruses were shown to be
essential for the viral life cycle [11–16].
The use of direct acting antivirals is one of the most important
new therapeutic approaches for treating infections with hepatitis C
virus (HCV), a close relative of DENV. Notably, AHs in HCV
NS4B and NS5A were found to be amenable to pharmacological
inhibition [11,17] indicating that AHs could serve as novel
antiviral targets. Our recent data emphasizes the significance of
the amino terminal AH of NS4A in the DENV life cycle and
demarcate it as potential target for the design of novel antiviral
therapy [6]. In this report, we describe a novel protocol for
recombinant production of a peptide comprising the first 48 amino
acids of NS4A, NS4A(1–48), and containing the above mentioned
AH. Production of milligram amounts of NS4A(1-48) is a crucial
prerequisite for biophysical and in particular NMR experiments
on NS4A(1-48). Such studies are urgently needed as a starting
point for the rational design of new strategies to inhibit the activity
of this NS4A region in the virus life cycle.
It is a common strategy to express short peptides as a fusion with
another protein in order to avoid the well-known degradation of
short peptides in bacterial cells. However, expression of fusion
proteins is complex and does not always follow predictions. Hence,
it is necessary to test several fusion strategies in search for a highly
efficient protocol that works for a given peptide. Several different
proteins have been described in the literature as fusion tags for
peptide production [18,19]. We tested glutathion S-transferase
(GST), the immunoglobulin-binding domain of streptococcal
protein G (GB1), and yeast ubiquitin as fusion partners of
NS4A(1-48) in our quest for an effective production strategy of this
peptide in E. coli. For DENV NS4A(1-48) a dual fusion tag in
combination with a tobacco etch virus (TEV) protease cleavage
site revealed the highest peptide yields. Our aim was to establish a
general protocol for production and purification of decent
amounts of wild type NS4A(1-48) as well as of various mutated
forms of the peptide. Such mutants are quite useful in an in-depth
structure-function-analysis of proteins.
Materials and Methods
Materials
E. coli Mach 1 cells obtained from Life Technologies GmbH
(Darmstadt, Germany) were used for cloning purposes. E. coli
BL21-(DE3) (Agilent Technologies, Inc., Santa Clara, CA, USA)
or E. coli BL21 (GE Healthcare, Freiburg, Germany) strains were
used for peptide expression. All enzymes used for cloning were
obtained from MBI Fermentas (St. Leon-Rot, Germany) if not
stated otherwise. Synthetic oligonucleotides were from BioTez
(Berlin, Germany). Plasmid pGEX-4T-2 was obtained from GE
Healthcare. The plasmid pTKK19ubi was a kind gift from
Toshiyuki Kohno (Mitsubishi Kagaku Institute of Life Sciences
(MITILS), Machida, Tokyo, Japan) [20] and pRK793 (plasmid
#8827) was obtained from the Addgene plasmid depository
(http://addgene.org). PCR purification kit, gel extraction kit
(QIAquick), miniprep kit (QIAprep spin) and Ni–NTA agarose
were all from Qiagen (Hilden, Germany). Difco LB broth was
purchased from BD Biosciences (Heidelberg, Germany). Ampicil-
lin and kanamycin were from AppliChem (Darmstadt, Germany),
Isopropyl b-D-1-thiogalactopyranoside (IPTG) was from Boehrin-
ger (Mannheim, Germany). [15N] ammonium chloride and
[13C6]-glucose were from Euriso-top (Saarbru¨cken, Germany).
Protein standards were obtained from MBI Fermentas and Sigma-
Aldrich (Munich, Germany). Glutathion-sepharose 4B was
purchased from GE Healthcare. All other chemicals were from
Sigma-Aldrich, Roth (Karlsruhe, Germany) or Merck (Darmstadt,
Germany) unless stated otherwise.
Construction of NS4A(1-48) expression vectors
NS4A(1-48) plasmid constructs with a single fusion
tag. We first cloned NS4A(1-48) into a modified pTKK19ubi
vector (see below), which codes for an amino terminal yeast
ubiquitin fusion. The peptide bond between ubiquitin and a
defined peptide insert in the expressed fusion protein can be
cleaved by yeast ubiquitin hydrolase. This strategy enables the
production of a NS4A(1-48) peptide without any artificial
overhangs. In order to simplify cloning of inserts into pTKK19ubi
vector [20], we modified the original pTKK19ubi by introducing
silent mutations that generate a unique SacII endonuclease
cleavage site at the carboxy-terminal end of the ubiquitin coding
sequence. In detail, the original codons for Leu 73, Arg 74 and Gly
75 in the ubiquitin coding sequence of pTKK19ubi are substituted
with ctc, cgc, and ggc, respectively, in the new pTKK19ubi/SacII.
Plasmid pUbi-NS4A(1–48) was obtained by cloning an optimized
sequence coding for amino acids 1 to 48 of NS4A from dengue
virus type 2 (GenBank: NP739588) into pTKKubi/SacII. Gene
optimization was performed using the GeneOptimizerH software
provided by GeneArtH [21]. To construct the plasmid, four
complementary synthetic oligonucleotides (sequences 1 to 4,
table 1) were annealed, ligated and subjected to a PCR-
amplification with two shorter primers (9 and 10, table 1)
containing the restriction sites for SacII and SalI. The purified
fragment was cut by SacII and SalI and then ligated into
dephosphorylated pTKK19Ubi/SacII.
Second, a plasmid for expression of the NS4A peptide as protein
fusion with the immunoglobulin-binding domain of streptococcal
protein G (GB1) at the amino terminus was obtained by cloning
the optimized sequence coding for NS4A(1-48) into the vector
pGEV2 [22] using the four synthetic oligonucleotides 1 to 4
(table 1). PCR amplification was performed with different primers
(5 and 6) in order to introduce a nucleotide sequence that codes for
the first six residues of a tobacco etch virus (TEV) protease
cleavage site (ENLYFQ) in front of the NS4A coding sequence.
The primers contained BamHI and XhoI restrictions sites at their
59 and 39 ends, respectively. This fragment was ligated into
dephosphorylated pGEV2 to yield pGEV-NS4A(1-48). As TEV
protease recognizes E-X-X-Y-X-QQ(G/S), and the first amino
acid of the NS4A peptide is serine, a NS4A(1-48) peptide without
any artificial overhang can be produced with this vector as well.
Third, we engineered a plasmid for expression of NS4A(1-48) as
protein fusion with an amino terminal glutathion-S-transferase
(GST) following the strategy described above for pGEV-NS4A
(1-48). The insert coding for NS4A(1-48) was ligated into a
dephosphorylated pGEX-4T-2 vector. The resulting construct was
named pGEX-TEV-NS4A(1-48).
NS4A(1-48) plasmid construct with a dual fusion
tag. Efficient separation of NS4A(1-48) from GB1 after TEV
protease cleavage was impossible when utilizing pGEV-NS4A(1-
48). In order to avoid this problem we extended the GB1-NS4A(1-
48) fusion by an amino terminal GST affinity tag. For this purpose
the GB1-NS4A(1-48) sequence was amplified with a 59-primer
containing an EcoRI site (7, table 1) and a commercially available
T7-terminator primer (8, table 1). The restricted insert was cloned
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into the pGEX4T-2 vector using the EcoRI and XhoI sites. The
obtained vector pGEX-GB1-NS4A(1-48) was used to produce the
GST-GB1-NS4A fusion protein in E. coli.
Tail-to-tail mutagenesis was used to obtain the mutant NS4A
peptide carrying L6E and M10E substitutions (pGEX-GB1-
NS4A(1-48; L6E, M10E) [23] using kappa HiFi DNA polymerase
(Kapa Biosystems Cambridge, MA, USA). The forward primer
(11, table 1) carried the mutations while the reverse primer (12,
table 1) annealed to the opposite strand, with their 59-ends
adjacent to each other. Subcloning into pGEX4T-2 was
performed as described for the wild type peptide. The correct
sequence of all constructs was verified using DNA sequencing
(Seqlab, Go¨ttingen, Germany).
Expression of NS4A(1-48) fusion proteins
BL21 cells were transformed with pGEX-TEV-NS4A(1-48),
pGEX-GB1-NS4A(1-48) or the mutant plasmid pGEX-GB1-
NS4A(1-48; L6E, M10E). BL31(DE3) cells were used for pUbi-
NS4A(1-48) and pGEV-NS4A(1-48), respectively. Recombinant
protein was produced in LB medium supplemented with the
appropriate antibiotics (ampicillin or kanamycin, 100 mg/ml).
Uniformly [15N] or [13C, 15N] isotope-labeled NS4A(1-48) was
expressed at 37uC in M9 medium containing [13C6] or [
12C6]
glucose and [15N] ammonium chloride as the sole carbon and
nitrogen sources, respectively. Each 1 L expression medium was
inoculated with an aliquot of a 50 ml overnight culture to an
optical density of 0.1 at 600 nm (OD600). Gene expression was
induced at an OD600 of 0.8 by addition of an ITPG stock to a final
IPTG concentration of 1 mM. Cells were incubated under gentle
agitation (150 rpm) and harvested 5 hours after induction by
centrifugation (50006 g, 4uC, 30 min). Cell pellets were washed
once in PBS buffer, spun down and stored at 220uC. Protein
expression was verified using SDS-PAGE with Coomassie staining.
Purification of GST-GB1-NS4A(1-48) fusion proteins and
their proteolytic cleavage
Pellets of pGEX-GB1-NS4A(1-48) or pGEX-GB1-NS4A(1-48;
L6E, M10E) transformed cells harvested from 1 L expression
culture, respectively, were thawed and resuspended on ice in
25 ml lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl,
1 mM DTT, 0.5 mM EDTA) supplemented with protease
inhibitors (Complete mini, Roche, Penzberg, Germany). Cells
were lysed using 4-5 cycles in a Microfluidizer M-100P
(Microfluidics, Worcestershire, UK). The crude lysate was clarified
by centrifugation (500006 g, 4uC, 30 min). Subsequent purifica-
tion steps were performed at 22uC. The supernatant was applied
onto a gravity flow column (column volume (CV) of 5 ml) packed
with GSH sepharose 4B (GE Healthcare) and pre-equilibrated
with lysis buffer. Unbound material was removed by washing with
10 CV of lysis buffer. When utilizing the mutant plasmid, on
column cleavage of the GST-GB1-NS4A(1-48; L6E, M10E) fusion
protein with 10 mM TEV protease (corresponding to a peptide to
TEV ratio of about 100) was performed in standard buffer at 22uC
overnight. The flow-through as well as the wash fractions (5 CVs)
containing the free NS4A(1–48; L6E, M10E) peptide and TEV
protease were pooled and concentrated to 5 ml using a Vivaspin
20 centrifugal concentrator (MWCO: 3 kDa, Sartorius, Go¨ttin-
gen, Germany). Separation of TEV protease from NS4A mutant
peptide was accomplished with a HiLoad 16/60 Superdex 75 prep
grade column (GE Healthcare) on an A¨KTA purifier system at
22uC with a flow rate of 1 ml/min. Interestingly, the GST-GB1-
NS4A(1–48) wild type fusion protein could not reliably be digested
under these standard conditions. Here, cell lysis had to be
performed in lysis buffer supplemented with 0.5 M urea. GSH-
binding and on column cleavage had to be done in the presence of
0.5 M urea and at a higher TEV concentration (50 mM, peptide to
TEV ratio of about 10). Flow-through and wash was collected
after TEV digestion and concentrated using Vivaspin 20
centrifugal concentrator. TEV-protease and urea was removed
from the concentrated peptide solution using a Highload 16/60
Superdex 75 prep grade column, equilibrated in 50 mM Tris-HCl
Table 1. Primers used for amplification of NS4A (1–48).
Oligo Sequence (59-39)
1 agcctgaccctgaatctgattaccgaaatgggtcgtctgccgacctttatgacccagaaagcacgtgatgcactggataatctgg
2 cagttctgcataccgctgaagccggtggtcgtgcatataatcatgcactgagcgaactgtaag
3 tgctttctgggtcataaaggtcggcagacgacccatttcggtaatcagattcagggtcaggct
4 gatccttacagttcgctcagtgcatgattatatgcacgaccaccggcttcagcggtatgcagaactgccagattatccagtgcatcac
5 ggaggaggatccgaaaacctgtattttcagagcctgaccctgaatctgattacc
BamHI
6 ggaggagtcgacctcgagttacagttcgctcagtgc
XhoI
7 gcgcgaattcagtacaagcttgctctgaacgg
EcoRI
8 gctagttattgctcagcgg (T7-Terminator-Primer; Novagen #69337-3)
9 ggaggaccgcggcggtagcctgaccctgaatctga
SacII
10 ggaggagtcgacctcgagttacagttcgctcagtgc
SalI
11 gaaattaccgaagagggtcgtctgccgac
12 attcagggtcaggctctgaaaatacaggtt
Note: The sequences of the restriction sites used for cloning are underlined, the name of the enzyme is given below.
doi:10.1371/journal.pone.0086482.t001
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pH 8, 150 mM NaCl at a flow rate of 1 ml/min. NS4A
containing fractions were pooled and concentrated. Cleavage,
separation efficiency and final purity of the NS4A peptides were
evaluated using SDS-PAGE analysis, and concentrations were
calculated by measuring the absorption at 280 nm. NS4A(1–48)
and the mutant peptide were kept at 4uC for short-term storage or
rapidly frozen in liquid nitrogen prior to long-term storage at
280uC.
TEV protease expression
TEV protease was produced using the plasmid pRK793
(Addgene). This plasmid codes for TEV fused to highly soluble
maltose-binding protein that cleaves itself in vivo to generate a His-
tagged TEV protease catalytic domain. Because of its S219V
mutation this enzyme does not show the wild type typical auto-
inactivation and allows the production of a stable and highly active
enzyme. Expression and purification of the protease was
performed as described [24].
Figure 1. NS4A(1–48) coding sequence. ClustalW alignment [40] of the NS4A(1–48) coding sequence as found in the viral genome of DENV type
2 and following optimization for E. coli expression [21].
doi:10.1371/journal.pone.0086482.g001
Figure 2. Comparative expression of NS4A(1–48) constructs containing single fusion tags. (A) SDS-PAGE analysis of the relative
expression levels of NS4A fusions with ubiquitin (Ubi-NS4A(1–48)), glutathion-S-transferase (GST-NS4A(1–48)) and immunoglobulin-binding domain
of streptococcal protein G (GB1-NS4A(1–48)). Aliquots of the expression cultures taken before (0) or 3 hours after IPTG induction (I) were applied.
Aliquots of the supernatants after cell lysis (S) are shown as well. (B) TEV cleavage of the purified GB1-NS4A(1–48) fusion protein. Purified GB1-
NS4A(1–48) fusion protein after size exclusion chromatography before (2) and after (+) TEV digestion together with a molecular weight marker (M;
M3546, Sigma) were applied.
doi:10.1371/journal.pone.0086482.g002
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Mass spectrometric analysis
Identity of the NS4A peptides was confirmed using mass
spectrometry. NS4A(1–48) peptide bands were excised from SDS
polyacrylamide gels and subjected to tryptic digestion. Peptide
fragment analysis was performed using an LC-MS/MS instrument
(nanoUPLC-QTOF Premier, Waters Corp., Milford, MA, USA).
These experiments were performed at the technology platform
Integrated Functional Genomics of the Interdisciplinary Center
for Clinical Research of the University of Mu¨nster, Germany.
NMR spectroscopy
2D (1H-15N)-BEST-TROSY spectra [25] were recorded at
303.15 K on a Varian UnityINOVA NMR spectrometer equipped
with a cryogenic Z-axis PFG triple resonance probe operating at a
proton frequency of 600 MHz. Data were processed with
NMRPipe [26] and analyzed with CcpNmr analysis [27]. NMR
samples contained 1 mM [15N] labeled NS5A(1–48) or NS4A
(1–48; L6E, M10E), respectively, in 50 mM sodium phosphate
buffer (pH 6.8) with 10% (v/v) deuterium oxide and 0.03% (w/v)
NaN3.
Results and Discussion
Codon adaption of the NS4A(1–48) coding sequence
Only negligible amounts of NS4A peptide could be obtained
when the original DENV type 2 cDNA sequence encoding the first
48 residues of NS4A, NS4A(1–48), was used in a pGEX expression
vector. This may be explained by the fact that the viral DNA
sequence for NS4A(1–48) is not optimal for expression in E. coli
cells, due to different codon usage. Specifically several codons for
leucine, isoleucine and arginine occurring in the viral gene
sequence are ‘‘rare codons’’ in E. coli (Fig. 1). Rare codons are
known to cause translational problems such as low protein
expression and frame shifts [28]. Thus the codons were optimized
for expression in E. coli cells and chemically synthesized
oligonucleotides were used to create a synthetic NS4A(1–48)
DNA cassette, which was then used to generate several NS4A
(1–48) expression constructs.
Expression yields of NS4A(1–48) strongly vary between
different fusion tags
To identify the ideal conditions for NS4A(1–48) expression, the
expression levels of codon-optimized NS4A(1–48) linked to three
different kinds of fusion tags in E. coli cells were tested (Fig. 2A). E.
coli BL21 harboring pGEX-TEV-NS4A(1–48) and BL21(DE3)
cells harboring pUbi-NS4A(1-48) or pGEV-NS4A(1–48) were
induced with IPTG for the indicated time, a band corresponding
to the full-length NS4A(1–48) fusion protein was detected in the
Coommassie-stained gel for the GST and the GB1 fusions. A full-
length NS4A(1–48) fusion protein could not be detected for Ubi-
NS4A(1–48) using Commassie staining. However, western blot
analysis confirmed its expression (data not shown). Highest
expression levels of NS4A(1–48) were detected with the GB1
fusion tag. As all the plasmids contained the same optimized NS4A
sequence the GB1 domain seems to account for these high
expression levels presumably by stabilizing the NS4A(1–48)
peptide. In addition, only the GB1-NS4A(1–48) fusion protein
could be efficiently extracted to the soluble fraction after cell lysis
without adding detergents. These findings are in line with previous
observations [18,29]. The average yields for the three expression
constructs are summarized in the upper part of table 2. The
highest amount of target peptide was produced with pGEV-
NS4A(1–48). Subsequently, the GB1-NS4A(1–48) fusion was
purified as described [18], however, TEV protease was used
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instead of Factor Xa. The optimum recognition site for TEV is
Glu-Asn-Leu-Tyr-Phe-Gln-(Gly/Ser) (ENLYFQ(G/S)) and cleav-
age occurs between the Gln and Gly/Ser residues [30]. DENV
NS4A starts with serine and thus TEV cleavage allows a very
specific and efficient removal of the fusion tag without any
artificial overhang. Briefly, the GB1 fusion protein was extracted
from the cell lysate by a simple heating step followed by size
exclusion chromatography yielding approximately 90% pure
Figure 3. Expression/cloning region of pGEX-GB1-NS4A(1–48). The GB1-NS4A(1–48) sequence was inserted into pGEX-4T-2 between the
EcoRI and XhoI sites. Protease recognition motifs are underlined while the cleavage sites are marked by triangles. The two thrombin sites, which
originate from the vector backbone of pGEX and pGEV, respectively, are shown in brackets and were not used in our protocol. Note that TEV
digestion produces a native NS4A peptide.
doi:10.1371/journal.pone.0086482.g003
Figure 4. Expression of NS4A(1–48) wild type and mutant peptides using a dual GST-GB1 tag. (A) Relative expression levels of GST-GB1-
NS4A(1–48) and the GST-GB1-NS4A(1–48; L6E, M10E) mutant were analyzed by SDS-PAGE using aliquots of the expression cultures. Shown are
samples obtained from culture at 0 (0) or 3 hours (I) following IPTG induction or the supernatant after cell lysis (S). (B) TEV digest of GST-GB1-NS4A(1–
48) wild type and mutant protein fusions. Aliquots of GSH-purified supernatants of wild type and mutant fusion proteins before and after TEV
cleavage are shown. Note that besides the GST-GB1-NS4A(1–48) full-length product also shorter fragments, likely GST-GB1 and other truncation
fragments, marked by asterisks were produced, which are present in the GSH-purified samples already prior to TEV cleavage. Because staining of free
NS4A(1–48) peptides is very faint under the conditions used, the progress of the TEV digest is monitored by observing the decrease of the band for
the dual tagged GST-GB1-NS4A(1-48) fusion protein in parallel with an increase of the band for the free GST-GB1 dual tag. A densitometric analysis of
the respective bands revealed a cleavage efficiency of approximately 50% for the wild type peptide.
doi:10.1371/journal.pone.0086482.g004
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fusion protein. TEV cleavage of the GB1 fusion protein was
complete after about 16 h when using a fusion protein to protease
ratio of about 100 (Fig. 2B). However, we were not able to
efficiently separate the cleaved NS4A(1–48) peptide from the GB1
domain. Separation by size exclusion chromatography was
hampered by similar elution behavior of both molecules, which
have similar molecular weights (5223.7 Da for NS4A(1–48) and
7585.3 Da for GB1). Thus IgG sepharose affinity chromatography
was used following an established protocol [22]. However, the
GB1 domain could not be completely removed even when IgG
sepharose was applied in large excess. This suggests that the
heating step might have caused misfolding of a substantial fraction
(up to 20%) of GB1 causing the observed leakage during affinity
chromatography. Subjecting the digest reaction to diverse reverse
phase chromatography resins did not yield satisfying results either.
The target NS4A(1–48) peptide showed a strong tendency to
remain on the column even at high acetonitrile concentrations,
presumably due to its amphipathic nature (data not shown).
Consequently, the highest purity that could be achieved for
untagged NS4A(1–48) was about 80% with an average recovery of
60% (see Table 2).
Additional tagging of GB1-NS4A with GST allows a
simplified separation of NS4A(1–48) from the fusion tag
Due to the difficulties in separating NS4A(1–48) from GB1 after
TEV protease cleavage as described above, we decided to add an
additional amino terminal GST tag to the protein (Fig. 3). The
relative expression levels achieved with this construct and the
respective mutant construct were evaluated using SDS-PAGE
(Fig. 4A). The data demonstrate proper and stable expression of
NS4A(1–48) fusion proteins. The GST-GB1 fusions could be easily
purified using GSH sepharose. The average yields of the GST-
GB1-NS4A peptide fusions are given in Table 2. TEV cleavage
under standard conditions could efficiently remove the dual tag
from the NS4A(1–48; L6E,M10E) mutant peptide. However, the
GST-GB1-NS4A(1–48) wild type construct showed unexpectedly
low cleavage efficiency (Fig. 4B).
Addition of urea improves the TEV cleavage of the wild
type NS4A(1–48) peptide
GST is known to form dimers in solution [31–33]. Examples of
GST-induced oligomerization of GST fusion proteins can be
found in the literature [34–36]. Such a GST-induced oligomer-
ization might also explain the observed resistance of a substantial
fraction of wild type GST-GB1-NS4A(1–48) to TEV cleavage
under standard conditions (Fig. 4B). Previous results from our
laboratory indicate that the amino terminal AH of NS4A plays a
role in the homo-oligomerization of NS4A [6]. We speculated that
the purified GST-GB1-NS4A(1–48) peptides might self-associate
and thus block the TEV recognition site (see Fig. 5A for
explanation). The NS4A mutant peptide, which is expected to
show a reduced self-association, was easily cleaved supporting the
above notion. We optimized the TEV digestion reaction
conditions with the aim to decrease the NS4A peptide self-
association without reducing the proteolytic activity of TEV.
Denaturing or chaotropic reagents like urea are typically used to
Figure 5. Optimization of TEV protease cleavage conditions. (A) A schematic model explaining the resistance of the GST-GB1 dual tagged
wild type NS4A(1–48) peptide to TEV cleavage. Scissors illustrate the protease while the triangles represent the position of the cleavage sites. GST
induced oligomerization of wild type NS4A(1 48) may block the protease cleavage site. (B) Analysis of the urea tolerance of TEV protease activity. GST-
GB1 tag removal from NS4A(1 48; L6E, M10E) in the presence of different concentrations of urea (M). Fusion peptides were incubated with TEV
protease at 20uC for 16 h at a fusion peptide to protease molar ratio of approximately 100. (C) Binding properties of GST-GB1-NS4A(1–48) to GSH
sepharose in the presence of urea. Equal amounts of the fusion peptide were subjected to a mini-scale GSH-affinity chromatography in the presence
of different concentrations of urea (M). Input, flow-through and elution fractions were analyzed by 15% SDS-PAGE. (D) TEV cleavage efficiency of wild
type NS4A(1–48) peptide in the presence of urea. GST-GB1 tag removal from NS4A(1–48) in the presence of different concentrations of urea given in
Molars. Fusion peptides were incubated in the absence (2) or presence (+) of TEV protease at 20uC for 16 h. The different ‘‘+’’ font sizes indicate the
increasing amounts of TEV protease with fusion peptide to protease molar ratios of approximately 100, 50 and 10. The progress of the TEV digest is
monitored by observing the decrease of the band of the dual tagged GST-GB1-NS4A(1–48) fusion protein and a parallel increase of the free GST-GB1
dual tag band (B, D).
doi:10.1371/journal.pone.0086482.g005
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break up such aggregates. TEV activity studies by Sun et al.
suggested that a recombinant TEV protease can retain most of its
activity at relatively high concentrations of denaturants such as
2 M urea [37]. In contrast Waugh et al. reported a lower urea
tolerance of 0.5 M for TEV [38]. Therefore, we first tested the
GST-GB1-NS4A(1–48; L6E, M10E) mutant construct, which
easily can be digested without additives, to assay the urea tolerance
of TEV protease under our experimental conditions. At low urea
concentrations (up to 0.5 M), no loss of TEV activity was observed
(Fig. 5B). Higher urea concentrations (1–2 M) resulted in a
significant activity loss of more than 50%, as described by Waugh
[38]. Our results indicate that the NS4A peptide aggregation is
perhaps a cooperative process. Therefore, addition of chaotropic
molecules early on in the purification process might further
improve the final yield of target protein. In order to add urea
already to the lysis buffer further optimization was required. It was
important to ensure that GST binding to GSH sepharose will not
be affected by the added urea. An earlier study indicated that GST
binds to GSH sepharose in presence of chaotropic reagents like
2–3 M guanidine hydrochloride or urea [39]. We independently
assessed the binding properties of GST-GB1-NS4A(1–48) to GSH
sepharose in the presence of increasing urea concentrations
(Fig. 5C). Addition of 0.5 M of urea did not alter the binding
behavior of GST to GSH sepharose. However, higher urea
concentrations resulted in a drastic shift of the GST-GB1-
NS4A(1–48) peak from the elution to the flow-through fractions.
Next we assayed the TEV cleavage efficiency for the double
tagged wild type NS4A(1–48) fusion construct in the presence of
increasing urea concentrations. Conveniently, 0.5 M urea was
sufficient to initiate the removal of GST-GB1 tag (figure 5D). Yet,
Figure 6. Purification of recombinant NS4A(1–48) wild type and mutant peptides. The 15% SDS-PAGE gel containing samples from various
steps in the purification procedure is shown on the left. The wild type peptide is shown in (A) while the mutant is shown in (B). The supernatant after
cell lysis is shown in lane 1. The lysate containing the peptide was loaded on a GSH sepharose column (lane 2), and cleaved by TEV protease on the
column, the cleaved protein is shown in lane 3. The GSTfusion tag remained bound to the column, while the NS4A(1–48) peptide was collected from
the flow-through (lane 4). The peptide was further purified by size exclusion chromatography (lane 5). The mutant peptide was purified using the
same strategy (B). The respective size exclusion chromatography profiles (HiLoad 16/60 Superdex 75 prep grade) of the flow-through fraction from
the TEV protease on column cleavage step - mainly containing TEV protease and NS4A(1–48; L6E, M10E) or NS4A(1–48) peptides - are shown on the
right with the matching SDS-PAGE analysis of the NS4A containing fractions.
doi:10.1371/journal.pone.0086482.g006
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TEV protease amounts had to be increased at least 5-fold
compared to the cleavage reaction of the mutant peptide.
Nevertheless, under these conditions, nearly complete removal of
GST-GB1 from the wild type NS4A(1–48) peptide was achieved.
The GST-GB1 fusion allows a nearly identical purification
protocol for both wild type and mutant NS4A peptides
Production of diverse mutant forms of NS4A(1–48) besides the
wild type is necessary for an in-depth structure-function-analysis.
Our aim was, to establish a general purification procedure
applicable to various NS4A(1–48) mutant peptides. Therefore,
purification steps that are sensitive to changes in peptide charge or
hydrophobicity, as it would be the case when applying ion
exchange or reverse phase chromatography, were avoided. The
feasibility of our simple purification procedure, which is based
exclusively on GSH-affinity and size exclusion chromatography, is
demonstrated for the wild type peptide and for the NS4A(1–48;
L6E, M10E) mutant as an example. This NS4A(1–48) mutant
carries glutamate substitutions at positions 6 and 10 instead of
leucine and methionine, respectively, resulting in a shift of the
isoelectric point from 6 to 5 and a considerably decreased
hydrophobicity of the peptide. The purification progress for the
wild type and the mutant NS4A(1–48) peptides is summarized in
figure 6. In both cases highly purified peptides could be obtained
after size exclusion chromatography. The identity of the peptides
was confirmed by in-gel tryptic digestion of the electrophoretically
separated protein band and mass spectrometric peptide mapping.
As summarized in table 2 we could obtain up to 3 mg untagged
wild type and up to 4 mg mutant peptide of very high purity
(approx. 98%) from 1 liter culture in rich medium. These values
indicate an almost complete TEV cleavage as well as an efficient
separation of the peptides from the dual tag, which was not
possible with the GB1 single tag system. Thus, our dual tag
strategy provides an efficient way for producing NS4A(1–48) in
E.coli.
Peptide labeling with stable isotope and initial nuclear
magnetic resonance spectra
Peptides labeled with the stable isotopes 15N and 13C can be
studied in great detail by nuclear magnetic resonance (NMR)
spectroscopy. Solution NMR is the method of choice for the
structural investigation of conformationally flexible peptides.
Using the double tagged GST-GB1-NS4A(1–48) fusion protein
we could easily produce even higher amounts of labeled NS4A(1–
48) by growing the E. coli cells in minimal medium supplemented
with [15N] ammonium chloride with either [12C6] or [
13C6]
glucose as sole nitrogen and carbon sources (Table 2). Production
of uniformly 15N-labeled NSA4(1–48) peptides in minimal
medium resulted in very similar peptide yields and purity as in
case of doubly labeled peptide. 2D (1H-15N)-BEST-TROSY
spectra of NS4A wild type and mutant peptides in aqueous buffer
are shown in figure 7. The position and low spectral dispersion of
the observed amide 1H-15N cross signals indicate unstructured
peptides. This is in good agreement with our earlier circular
dichroism (CD) data on these two peptides in aqueous buffer [6].
These results indicate that the amount of highly pure isotope-
labeled NS4A peptides produced using the described double tag
strategy is sufficient for future multidimensional NMR experi-
ments. These experiments are required for peptide resonance
assignment and for gathering information regarding the structure
of the peptides and their dynamics in presence of membranes or
membrane mimetic model systems.
Conclusion
Our GST-GB1 fusion approach represents a valuable tool for
preparing milligram amounts of unlabeled or isotope labeled
NS4A(1–48) peptides. This is an important prerequisite for a
detailed analysis of the structure-function relationship of the amino
terminal region of NS4A with the aim to elucidate the mechanism
how this region interacts with membranes. The results may lead to
new antiviral strategies to fight DENV. In general the presented
production procedure may also aid the characterization of other
aggregation prone proteins that are frequently coded in viral
genomes.
Figure 7. Recorded 2D (1H, 15N)-BEST-TROSY spectra of the purified NS4A peptides. Spectrum of 0.5 mM [15N]-NS4A(1–48) wild type (A)
and of 1 mM mutant (L6E, M10E) peptide (B) in 50 mM sodium phosphate buffer, pH 6.8. Data were recorded at 30uC.
doi:10.1371/journal.pone.0086482.g007
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